Luye Pharma Group Ltd.

LYPHF · OTC
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Activities
Net Income$839$700$670-$75
Dep. & Amort.$791$702$671$582
Deferred Tax$0$0$0-$312
Stock-Based Comp.$21$21$25$50
Change in WC-$1,234$398$320-$418
Other Non-Cash-$250-$225-$33$355
Operating Cash Flow$168$1,595$1,654$182
Investing Activities
PP&E Inv.-$596-$633-$1,164-$1,542
Net Acquisitions-$634-$1,380$0-$809
Inv. Purchases-$2,390-$1,628-$3,486-$3,976
Inv. Sales/Matur.$3,561$2,593$2,899$1,919
Other Inv. Act.-$1,412-$371$92$971
Investing Cash Flow-$1,471-$1,418-$1,658-$3,436
Financing Activities
Debt Repay.$1,876-$478-$666-$406
Stock Issued$0$923$189$1,044
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$1,080$397$531$1,241
Financing Cash Flow$2,956$842$54$1,879
Forex Effect$45-$104-$164-$52
Net Chg. in Cash$1,698$915-$115-$1,427
Supplemental Information
Beg. Cash$3,239$2,324$2,438$3,865
End Cash$4,937$3,239$2,324$2,438
Free Cash Flow-$1,541$430$490-$1,359